- Prophylactic Versus Endoscopy-driven Treatment of Crohn's Postoperative Recurrence: A Retrospective, Multicentric, European Study [PORCSE Study](2024)
Auteurs: Peter Bossuyt
- Real-world Effectiveness and Safety of Risankizumab in Patients with Moderate to Severe Multirefractory Crohn's Disease: A Belgian Multicentric Cohort Study(2024)
Auteurs: Dahham Alsoud, João Guedelha Sabino, Peter Bossuyt, Séverine Vermeire, Marc Ferrante
- Baseline Data and Measurement Instruments Reported in Observational Studies in Inflammatory Bowel Disease: Results from a Systematic Review(2024)
Auteurs: Peter Bossuyt
- Autoimmune Pancreatitis in Patients with Inflammatory Bowel Disease: A Real-World Multicentre Collaborative ECCO CONFER Study(2023)
Auteurs: Bram Verstockt, Peter Bossuyt
Pagina's: 1791 - 1799
- Early Versus Late Use of Vedolizumab in Ulcerative Colitis: Clinical, Endoscopic, and Histological Outcomes(2023)
Auteurs: Séverine Vermeire, Marc Ferrante, Peter Bossuyt, Gert De Hertogh
- Effect of 104 Weeks of Mirikizumab Treatment on Inflammatory Bowel Disease Questionnaire Scores Among Patients With Moderately to Severely Active Crohn's Disease(2023)
Auteurs: Peter Bossuyt
Pagina's: S809 - S809
- Mirikizumab Sustained Improvement on Fatigue in Patients With Moderately to Severely Active Crohn's Disease in the Phase 2 AMAG Study at Week 104(2023)
Auteurs: Peter Bossuyt
Pagina's: S816 - S816
- Long-term follow-up of the red density pilot trial: a basis for long-term prediction of sustained clinical remission in ulcerative colitis?(2023)
Auteurs: Pieter Sinonquel, Peter Bossuyt, João Guedelha Sabino, Bram Verstockt, Séverine Vermeire, Raf Bisschops
Pagina's: E880 - E884
- Patient-reported Outcomes and Disability Are Associated with Histological Disease Activity in Patients with Ulcerative Colitis: Results from the APOLLO Study(2023)
Auteurs: Bram Verstockt, Peter Bossuyt
Pagina's: 1046 - 1054
- ECCO Topical Review on Biological Treatment Cycles in Crohn's Disease(2023)
Auteurs: Peter Bossuyt
Pagina's: 1031 - 1045